- Country: USA
- Summary: Relenza (Zanamivir) Rotadisk, 5 mg
- UST Ref No: 125880467
- Deadline: 20 Sep 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: RZ-09052025
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
This is a NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT under the authority of FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements.
The Office of the Administration for Strategic Preparedness and Response (ASPR), Center for the Strategic National Stockpile (SNS) intends to award a sole source firm fixed price contract to:
Manufacturer NameGlaxoSmithKline LLC
410 Blackwell St. Research Triangle Park
Durham, NC, 27701
The purpose of this acquisition is to provide the United States Government (USG) with a pharmaceutical required to maintain minimum stockpiling capabilities for responding to public health events. Relenza (Zanamivir) Rotadisk, 5 mg are essential for readiness and response to national emergencies. Relenza (Zanamivir) is an antiviral drug that is active against both influenza type A and influenza type B viruses. Zanamivir is given by inhalation only.
The USG has a need to procure Relenza (Zanamivir) Rotadisk, 5 mg, a U.S. Food and Drug Administration (FDA)-approved and commercial pharmaceutical, to be utilized during national public health events. The USG intends to procure the following: quantity of 303,333 packages of Relenza (Zanamivir) Rotadisk 5 mg for the base year, quantity of 303,333 packages of Relenza (Zanamivir) Rotadisk 5 mg for optional year 1, quantity of 303,333 packages of Relenza (Zanamivir) Rotadisk 5 mg for optional year 2, quantity of 303,333 packages of Relenza (Zanamivir) Rotadisk 5 mg for optional year 3, quantity of 303,333 packages of Relenza (Zanamivir) Rotadisk 5 mg for optional year 4.
GlaxoSmithKline LLC is currently the sole manufacturer of Relenza (Zanamivir) Rotadisk, 5 mg. They have no relationships with resellers or distributors for this product. There are no other United States FDA-approved manufacturers for Relenza (Zanamivir) Rotadisk, 5 mg.
This notice is for informational and planning purposes and does not const... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINRelenza (Zanamivir) Rotadisk, 5 mg - USA Tender
The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE, a Government sector organization in USA, has announced a new tender for Relenza (Zanamivir) Rotadisk, 5 mg. This tender is published on USARFP under UST Ref No: 125880467 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-09-20.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
